KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Change in Cash (2016 - 2025)

Historic Change in Cash for NovoCure (NVCR) over the last 12 years, with Q3 2025 value amounting to $192.5 million.

  • NovoCure's Change in Cash rose 82746.68% to $192.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $155.4 million, marking a year-over-year increase of 37553.77%. This contributed to the annual value of -$76.5 million for FY2024, which is 16034.09% down from last year.
  • Latest data reveals that NovoCure reported Change in Cash of $192.5 million as of Q3 2025, which was up 82746.68% from $22.7 million recorded in Q2 2025.
  • Over the past 5 years, NovoCure's Change in Cash peaked at $330.1 million during Q3 2021, and registered a low of -$481.1 million during Q4 2021.
  • In the last 5 years, NovoCure's Change in Cash had a median value of $20.8 million in 2024 and averaged $5.2 million.
  • Within the past 5 years, the most significant YoY rise in NovoCure's Change in Cash was 232639.1% (2021), while the steepest drop was 455777.43% (2021).
  • Quarter analysis of 5 years shows NovoCure's Change in Cash stood at -$481.1 million in 2021, then soared by 73.35% to -$128.2 million in 2022, then soared by 167.12% to $86.1 million in 2023, then plummeted by 126.85% to -$23.1 million in 2024, then surged by 933.17% to $192.5 million in 2025.
  • Its last three reported values are $192.5 million in Q3 2025, $22.7 million for Q2 2025, and -$36.7 million during Q1 2025.